Yuan et al., 2022 - Google Patents
Probiotic therapy (BIO-THREE) mitigates intestinal microbial imbalance and intestinal damage caused by oxaliplatinYuan et al., 2022
- Document ID
- 18101204846731435523
- Author
- Yuan W
- Xiao X
- Yu X
- Xie F
- Feng P
- Malik K
- Wu J
- Ye Z
- Zhang P
- Li X
- Publication year
- Publication venue
- Probiotics and Antimicrobial Proteins
External Links
Snippet
Gastrointestinal mucositis associated with the use of chemotherapeutic drugs can seriously affect the quality of life of patients. In this study, a probiotic mixture, BIO-THREE, was used to alleviate intestinal damage caused by oxaliplatin in mice and human patients. Kunming …
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 0 title abstract description 109
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Probiotic therapy (BIO-THREE) mitigates intestinal microbial imbalance and intestinal damage caused by oxaliplatin | |
| Nagpal et al. | Human-origin probiotic cocktail increases short-chain fatty acid production via modulation of mice and human gut microbiome | |
| Suez et al. | Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT | |
| Pötgens et al. | Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction | |
| Motoori et al. | Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients | |
| Zhai et al. | Oral supplementation of lead-intolerant intestinal microbes protects against lead (Pb) toxicity in mice | |
| Bartosch et al. | Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota | |
| Bubnov et al. | Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice | |
| Wigner et al. | Probiotics in the prevention of the calcium oxalate urolithiasis | |
| Ali et al. | Modulation of JNK-1/β-catenin signaling by Lactobacillus casei, inulin and their combination in 1, 2-dimethylhydrazine-induced colon cancer in mice | |
| Qiao et al. | Pediococcus acidilactici strains improve constipation symptoms and regulate intestinal flora in mice | |
| Zhang et al. | Assessment of the safety and probiotic properties of Roseburia intestinalis: A potential “Next Generation Probiotic” | |
| Suwal et al. | The probiotic effectiveness in preventing experimental colitis is correlated with host gut microbiota | |
| Chan et al. | Transplant associated infections—The role of the gastrointestinal microbiota and potential therapeutic options | |
| Choi et al. | Dysbiosis of fecal microbiota from complement 3 knockout mice with constipation phenotypes contributes to development of defecation delay | |
| Jin et al. | Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota | |
| Khan et al. | Current status of probiotics for prevention and management of gastrointestinal cancers | |
| Huang et al. | Suppression of berberine and probiotics (in vitro and in vivo) on the growth of colon cancer with modulation of gut microbiota and butyrate production | |
| Fu et al. | Portulaca oleracea polysaccharides modulate intestinal microflora in aged rats in vitro | |
| Toe et al. | A prebiotic-enhanced lipid-based nutrient supplement (LNSp) increases Bifidobacterium relative abundance and enhances short-chain fatty acid production in simulated colonic microbiota from undernourished infants | |
| Liu et al. | Lactiplantibacillus plantarum reduced renal calcium oxalate stones by regulating arginine metabolism in gut microbiota | |
| Sun et al. | Assessment of the bifidogenic and antibacterial activities of xylooligosaccharide | |
| Liu et al. | A Synbiotic Ameliorates Con A‐Induced Autoimmune Hepatitis in Mice through Modulation of Gut Microbiota and Immune Imbalance | |
| Liang et al. | Lactobacillus gasseri LG08 and Leuconostoc mesenteroides LM58 exert preventive effect on the development of hyperuricemia by repairing antioxidant system and intestinal flora balance | |
| Ying et al. | Postbiotics in rheumatoid arthritis: Emerging mechanisms and intervention perspectives |